High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3889-3897

  Terwijn, Monique ^a   Kelder, Angèle ^a   Huijgens, Peter C ^a   Dräger, Angelika M ^a   Oussoren, Yvonne J M ^a   Scholten, Willemijn J ^a   Snel, Alexander N ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit J ^a   Biemond, Bart J ^b   Van Putten, Wim L J ^c   Van Der Velden, Vincent H J ^c   De Greef, Georgine E ^c   Valk, Peter J M ^c   Jongen Lavrecic, Mojca ^c   Löwenberg, Bob ^c   Brooimans, Rik A ^c   Gratama, Jan W ^c   Preijers, Frank W M B ^d   Van Gelder, Michel ^e   Wijermans, Pierre ^f   Legdeur, Marie Cecile ^g   Slomp, Jennita ^g   Kuball, Jurgen ^h   De Weerdt, Okke ⁱ   Verdonck, Leo F ^j   Pabst, Thomas ^k   Schanz, Urs ^l   Passweg, Jakob R ^m   Bargetzi, Mario ⁿ   Chalandon, Yves ^o   Hess, Urs ^p   Maertens, Johan ^q   Boeckx, Nancy ^q   Graux, Carlos ^r   Vekemans, Marie Christiane ^s   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HAGA HOSPITAL   (Netherlands)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ ST ANTONIUS HOSPITAL   (Netherlands)

^j ISALA HOSPITAL   (Netherlands)

^k UNIVERSITY OF BERN   (Switzerland)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ CANTONAL HOSPITAL AARAU   (Switzerland)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^p CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^s CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; YOUNG ADULT; ADOLESCENT; CONSOLIDATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; METHODOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; TUMOR RECURRENCE; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROCEDURES;

ADOLESCENT; ADULT; CONSOLIDATION CHEMOTHERAPY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; YOUNG ADULT;

EID: 84891654526     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9628     Document Type: Article

References (28)

1. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial-The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998 (Pubitemid 28452973)
2. Döhner H: Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007:412-419, 2007
3. Grimwade D, Hills RK: Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009:385-395, 2009
4. Valk PJ, Verhaak RG, Beijen MA, et al: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628, 2004
5. Kern W, Haferlach C, Haferlach T, et al: Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 112:4-16, 2008
6. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 26:4944-4951, 2008
7. San Miguel JF, Martínez A, Macedo A, et al: Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90:2465-2470, 1997 (Pubitemid 27392732)
8. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al: Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 24:1599-1606, 2010
9. Vidriales MB, San-Miguel JF, Orfao A, et al: Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 16:599-612, 2003
10. Feller N, van der Pol MA, van Stijn A, et al: MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18:1380-1390, 2004 (Pubitemid 39136748)
11. Kern W, Voskova D, Schoch C, et al: Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104: 3078-3085, 2004 (Pubitemid 39517010)
12. Venditti A, Buccisano F, Del Poeta G, et al: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96:3948-3952, 2000
13. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101:3398-3406, 2003 (Pubitemid 36857920)
14. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al: Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123:243-252, 2003 (Pubitemid 37305058)
15. MRD-AML-BFM Study Group, Langebrake C, Creutzig U, et al: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 24:3686-3692, 2006
16. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
17. Buccisano F, Maurillo L, Spagnoli A, et al: Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 21:582-588, 2009
18. Campana D: Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol 143:481-489, 2008
19. San Miguel JF, Vidriales MB, López-Berges C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746-1751, 2001
20. Pabst T, Vellenga E, van Putten W, et al: Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 119:5367-5373, 2012
21. Van der Reijden BA, de Wit L, van der Poel S, et al: Identification of a novel CBFB-MYH11 transcript: Implications for RT-PCR diagnosis. Hematol J 2:206-209, 2001 (Pubitemid 32633673)
22. Labopin M, Latouche A, Suciu S, et al: Definitions and evaluation of endpoints following stem cells transplantation - Recommendation from the European group for Blood and Marrow transplantation (EBMT). Presented at the 35th Annual Meeting of the European Group for Blood and Marrow Transplantation, Göteborg, Sweden, March 29-April 1, 2009
23. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 13:559-565, 2007 (Pubitemid 46225362)
24. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
25. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ: Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 153:421-436, 2011
26. van Rhenen A, van Dongen GA, Kelder A, et al: The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110:2659-2666, 2007 (Pubitemid 47523190)
27. van Rhenen A, Moshaver B, Kelder A, et al: Aberrant marker expression patterns on the CD34+ CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21:1700-1707, 2007 (Pubitemid 47086760)
28. van Rhenen A, Feller N, Kelder A, et al: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11:6520-6527, 2005 (Pubitemid 41338990)